Theravance Biopharma Inc (TBPH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Theravance Biopharma Inc stock (TBPH) is currently trading at $15.29. Theravance Biopharma Inc PE ratio is 25.14. Theravance Biopharma Inc PS ratio (Price-to-Sales) is 6.76. Analyst consensus price target for TBPH is $15.83. WallStSmart rates TBPH as Hold.
- TBPH PE ratio analysis and historical PE chart
- TBPH PS ratio (Price-to-Sales) history and trend
- TBPH intrinsic value — DCF, Graham Number, EPV models
- TBPH stock price prediction 2025 2026 2027 2028 2029 2030
- TBPH fair value vs current price
- TBPH insider transactions and insider buying
- Is TBPH undervalued or overvalued?
- Theravance Biopharma Inc financial analysis — revenue, earnings, cash flow
- TBPH Piotroski F-Score and Altman Z-Score
- TBPH analyst price target and Smart Rating
Theravance Biopharma Inc
📊 No data available
Try selecting a different time range
TBPH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Theravance Biopharma Inc (TBPH)
TBPH trades 403% above its Graham fair value of $3.88, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Theravance Biopharma Inc (TBPH) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, revenue growth. Concerns around peg ratio. Fundamentals are solid but monitor weak areas for improvement.
Theravance Biopharma Inc (TBPH) Key Strengths (5)
Every $100 of shareholder equity generates $45 in profit
Keeps $44 of every $100 in revenue after operating costs
Revenue surging 144.70% year-over-year
Keeps $99 of every $100 in revenue as net profit
98.82% of shares held by major funds and institutions
Supporting Valuation Data
Theravance Biopharma Inc (TBPH) Areas to Watch (4)
PEG ratio is negative or unavailable
Premium valuation at 6.8x annual revenue
Premium pricing at 3.1x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Theravance Biopharma Inc (TBPH) Detailed Analysis Report
Overall Assessment
This company scores 61/100 in our Smart Analysis, earning a C+ grade. Out of 9 metrics analyzed, 5 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with Return on Equity at 44.90%, Operating Margin at 43.60%, Profit Margin at 98.50%. Growth metrics are encouraging with Revenue Growth at 144.70%.
The Bear Case
The primary concerns are PEG Ratio, Price/Sales, Price/Book. Some valuation metrics including PEG Ratio (N/A), Price/Sales (6.76), Price/Book (3.13) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 44.90% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 144.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Operating Margin) and negatives (PEG Ratio, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TBPH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TBPH's Price-to-Sales ratio of 6.76x trades at a deep discount to its historical average of 46.39x (3th percentile). The current valuation is 100% below its historical high of 1496.35x set in Jun 2014, and 22% above its historical low of 5.54x in Sep 2021.
WallStSmart Analysis Synopsis
Data-driven financial summary for Theravance Biopharma Inc (TBPH) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Theravance Biopharma Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 107M with 145% growth year-over-year. Profit margins are strong at 98.5%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 145% YoY, reaching 107M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 4490.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Theravance Biopharma Inc maintain 145%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Theravance Biopharma Inc.
Bottom Line
Theravance Biopharma Inc offers an attractive blend of growth (145% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(8 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:28:08 AM
About Theravance Biopharma Inc(TBPH)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.